Company intelligence

Nouscom

BiotechSee connections →Compare with HighLife

Is this your company? Get featured or correct your listing →

Suggest a correction

Recent changes

  1. Oct 19, 2026Raised €120M Series D EU-Startups
  2. Oct 19, 2026New investor: Versant Ventures EU-Startups
  3. Oct 19, 2026New investor: Bpifrance EU-Startups
  4. Oct 19, 2026New investor: M Ventures (Merck KGaA) EU-Startups
  5. Oct 19, 2026New investor: 5AM Ventures EU-Startups
Earlier changes (1)
  1. Oct 19, 2026Nouscom Raises $135M To Push Cancer-Prevention Vaccine Toward Approval Pulse story

Funding History

1 event · sources dated per row
DateEventAmountValuationInvestorsSource
Oct 19, 2026Series D€120M—
M Ventures (Merck KGaA)LeadStartup Ticker · unverifiedEuropean Investment BankStartup Ticker · unverified5AM VenturesStartup Ticker · unverifiedAndera PartnersStartup Ticker · unverifiedBpifranceStartup Ticker · unverifiedVersant VenturesStartup Ticker · unverifiedRevelation PartnersAngelini IndustriesNeva SGRAngelini Ventures+5 more
EU-Startups

Investors

M Ventures (Merck KGaA)5AM VenturesAndera PartnersBpifranceEuropean Investment BankVersant Ventures

Latest Pulse

  1. Nouscom Raises $135M To Push Cancer-Prevention Vaccine Toward ApprovalSwiss biotech Nouscom raised $135M (€120M) in a Series D co-led by M Ventures, Merck KGaA's venture arm, and Revelation Partners, to fund a global trial of cancer-prevention vaccine NOUS-209 in Lynch syndrome carriers.→

Coverage Timeline

newest first
  1. Oct 19, 2026FUNDINGNouscom Raises $135M To Push Cancer-Prevention Vaccine Toward Approval$135M Series D ($120M)→

All Coverage

FUNDING

Nouscom Raises $135M To Push Cancer-Prevention Vaccine Toward Approval

Illustration for: Nouscom Raises $135M To Push Cancer-Prevention Vaccine Toward Approval
FUNDING$135M Series D ($120M)

Nouscom Raises $135M To Push Cancer-Prevention Vaccine Toward Approval

Swiss biotech Nouscom raised $135M (€120M) in a Series D co-led by M Ventures, Merck KGaA's venture arm, and Revelation Partners, to fund a global trial of cancer-prevention vaccine NOUS-209 in Lynch syndrome carriers.

DEEP DIVE

Related Companies

Shared investors
HighLife
Same sector
Scribe TherapeuticsAttovia TherapeuticsApnimedIambic TherapeuticsRetension PharmaceuticalsEli Lilly

Nouscom FAQ

Who are Nouscom's investors?

Nouscom's investors include M Ventures (Merck KGaA), 5AM Ventures, Andera Partners, Bpifrance, European Investment Bank, and 1 more.

Sources & methodologyshow
Where these figures come from

Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.

How we verify data · Suggest a correction